Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

Date: 13-11-2026

To,
The Deputy Manager
(Department of Corporate Services)
BSE Limited
P. J. Towers Dalal Street,
Fort, Mumbai- 400001

Sub: Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September, 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Ref.: Scrip Code: 512600
Security Id: ASTALLTD

Respected Sir/ Madam,

Pursuant to the Regulation 33 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation, 2015 (Listing Regulations), the Board of Directors at their meeting held on Today i.e. Friday, 13th November, 2026 have considered and approved, the Unaudited Standalone and Consolidated Financial Results of the company for the quarter and half year ended on 30th September, 2026 along with the limited review report of the auditors thereon.

The Auditors' Limited Review Report on the said financial results is also attached herewith.

The Board Meeting commenced at 05:00 p.m. (IST) and concluded at 05:50 p.m. (IST)

The aforesaid information is also available on the website of the Company https://astallabs.com.

We request you to take the aforesaid information on record for dissemination through your website.

Thanking you,

Yours Faithfully,

For Astal Laboratories Limited

Mahendra Kumar
(Company Secretary & Compliance Officer)
Membership No.: A71224

SATHULURI & CO.
CHARTERED ACCOUNTANTS

Limited Review Report on Standalone Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Astal Laboratories Limited

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **Astal Laboratories Limited** for the quarter and half year ended on 30th September, 2026, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation,2015, (the Regulation) as amended, (the "Listing Regulations').

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Off: 11-13-1377/2, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035.
Ph: 9391686797 Email: casathuluri93@gmail.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sathuluri & Co.
Chartered Accountants
(FRN. No.006383S)



CA S S Prakash
Partner
M.No. 202710

UDIN : 26202710AFAIFT2589

Place: Hyderabad
Date : 13-11-2026

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2026

Rs. (In Lakhs)

Sr. No	Particulars	3 Months ended	Preceding 3 Months ended	Corsponding 3 Months Ended Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to date figures for previous Period ended	Year to date figures for Previous year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue**						
	a) From operations	4,072.37	3,951.41	3,751.64	8,023.78	6,284.30	15,599.53
	b) Other Income (Refer to Note No.3)	15.38	3.21	3.27	18.59	8.88	19.16
	Total Revenue	**4,087.75**	**3,954.62**	**3,754.91**	**8,042.37**	**6,293.18**	**15,618.68**
2	**Expenses**						
	(a) Cost of Material Consumed	3,822.03	4,081.52	3,908.02	7,903.56	6,216.23	15,288.45
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(452.17)	(799.50)	(626.03)	(1,251.67)	(787.66)	(1,401.56)
		-		-		-	
	(d) Employees Benefits expenses	42.74	61.82	41.83	104.55	86.55	211.26
	(e) Finance Cost	39.11	32.79	30.91	71.89	60.99	140.91
	(f) Depreciation amortization expenses	18.46	17.74	12.24	36.20	24.25	68.84
	(g) Other Expenses	108.67	64.60	40.94	173.28	66.53	224.23
	Total Expenses	**3,578.84**	**3,458.97**	**3,407.92**	**7,037.81**	**5,666.90**	**14,532.12**
3	**Profit from ordinary activities before exceptonal Items (1 - 2)**	508.91	495.65	346.99	1,004.56	626.28	1,086.56
4	**Exceptional Items - Income/ (Expenses)**	-	-	-	-	-	-
5	***Profit from ordinary* activities before tax (3 - 4)**	508.91	495.65	346.99	1,004.56	626.28	1,086.56
6	Tax Expenses						
	(a) Current Tax	145.58	103.13	90.41	248.71	136.02	258.84
	(b) Deferred Tax	(15.79)	21.83	(1.68)	6.05	23.03	16.17
7	**Profit/(Loss) for the period (5 -6)**	379.12	370.69	258.26	749.80	467.22	811.55
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
9	**Total Comprehensive Income, net of tax (7 + 8)**	379.12	370.69	258.26	749.80	467.22	811.55
10	**Paid up equity share capital** (Face Value of Rs.10/- each)	4,379.89	4,379.89	1,077.00	4,379.89	1,077.00	4,223.11
11	**Earning per share** (of Rs.10/-each) not annualised						
	(a) Basic	**0.866**	**0.861**	**2.395**	**1.726**	**4.338**	**4.757**
	(b) Diluted	**0.862**	**0.857**	**1.972**	**1.719**	**3.568**	**4.310**

Notes:

1	The above Unaudited Standalone Financial Results of the company for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 13th November, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/
7	The Company has one Material Wholly Owned Subsidiary Company as on September 30, 2026.

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

STATEMENT OF STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30,2026

(Rs. In lakhs.)

	PARTICULARS	As at 30th September, 2026 (Unaudited)	As at 31-March 2026 (Audited)
	ASSETS		
1	**Non - current assets**		
(a)	Property, plant and equipment	1123.22	1135.84
(b)	Right-of-use-asset	65.08	74.85
(c)	Capital work in progress		
(d)	Investment property		
(e)	Intangible assets-Good will		
(f)	Financial assets		
	(i) Investment in Sriven Pharmachem India Pvt Ltd	27716.95	27716.95
	(ii) Loans	389.81	409.26
	(iii) Other financial assets		
	(iv) Balance with Banks		
(g)	Deferred tax Assets (Net)		
(h)	Other Non-current assets		0.00
	Total non-currrent assets	**29295.06**	**29336.89**
2	**Current assets**		
(a)	Inventories	4721.37	2877.54
(b)	**Financial assets**		
	(i) Investments		
	(ii) Trade receivables	7278.43	7230.17
	(iii) Cash and cash equivalents	342.35	353.34
	(iv) Other balances with banks		
	(v) Loans		
	(vi) Other financial assets	10.53	10.53
(c)	Other Current assests	33.95	148.72
	Total current assets	**12386.63**	**10620.31**
	TOTAL ASSETS	**41681.70**	**39957.20**
	EQUITY AND LIABILITIES		
1	**Equity**		
(a)	Share capital	4381.45	4223.12
(b)	Other equity	29529.67	28493.20
	Total Equity	**33911.12**	**32716.32**
2	**Non-current liabilities**		
(a)	Financial liabilities		
	(i) Long-term borrowings	250.08	36.59
	(ii) Deferred tax liabilities (net)	34.08	28.03
	(iii) Lease Liabilities		
	(iv) Other financial liabilities		

ASTAL LABORATORIES LIMITED

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

(b)	Provisions		
(c)	Other Non Current liabilities		
	Total non-current liabilities	**284.16**	**64.62**
3	**Current liabilities**		
(a)	Financial liabilities		
	(i) Borrowings	1375.06	1159.20
	(ii) Lease Liabilities		
	(iii) Trade payables	5393.41	5406.67
	(iv) Other financial liabilities	72.92	80.99
(b)	Provisions		
(c)	Other current Liabilities	645.03	529.40
	Total current liabilities	**7486.42**	**7176.26**
	Total Liabilities	**7770.58**	**7240.88**
	TOTAL EQUITY AND LIABILITIES	**41681.70**	**39957.20**

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

STATEMENT OF STANDALONE CASH FLOW STATEMENT AS AT SEPTEMBER 30, 2026

	PARTICULARS	30th September, 2026 Amount (Rs. In Lakhs) (Unaudited)	31st March, 2026 Amoun (Rs. In Lakhs) (Audited)
A.	**CASH FLOW FROM OPERATING ACTIVITIES: -**		
	Net Profit/(Loss) before tax as per statement of Profit & Loss	1,004.56	1,086.56
	Adjustment for: -		
	Depreciation	36.20	68.84
	Finance Cost	71.89	140.91
	Interest Income	(18.59)	(19.16)
	Operating Profit before working capital changes.	1,094.07	1,277.16
	Adjustment for: -		
	Changes in Trade Receivables	(48.26)	(4,463.77)
	Changes in Trade Payables	(13.26)	4,329.18
	Changes in Inventory	(1,843.83)	(1,401.56)
	Changes in Other Current Assets	114.77	(0.19)
	Changes in Other Non-Current assets		(0.53)
	Changes in Other Current liabilities	(133.07)	54.21
	Cash generated form operations	(829.58)	(205.50)
	Taxes paid (Net)	-	(102.08)
	Net cash generated from / (used in) Operating Activities	**(829.58)**	**(307.57)**
B.	**CASH FLOW FROM INVESTING ACTIVITIES: -**		
	Interest Income	18.59	19.16
	Purchase of Fixed Assets	(13.82)	(40.72)
	Investment in Sriven Pharma-Cash Consideration	-	(29.63)
	(Issue) / Recovery of Loans and advances	19.45	(0.00)
	Fixed Deposit with Banks	(35.98)	(77.28)
	Net cash from Investing Activities	**(11.77)**	**(128.47)**
C.	**CASH FLOW FROM FINANCING ACTIVITIES: -**		
	Interest Expense	(68.05)	(131.95)
	Interest Expense on Lease Liability	(3.85)	(8.97)
	Principal payment on Lease Liability	(8.07)	(13.38)
	Long Term Borrowings Taken	220.22	-
	Long Term Borrowings Repaid	(6.73)	(9.02)
	Issue of Shares		-
	Security Premium		-
	Share Warrets Amount received	444.99	617.98
	Net cash from (used in) Financing Activities	**578.52**	**454.67**
	Net (Decrese)/Increase in Cash & Cash Equivalent (A+B+C)	**(262.83)**	**18.62**

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

	Opening Balance of Cash & Cash Equivalents	**(1,077.78)**	**(1,096.40)**
	Cash on hand	7.60	0.02
	Balance With Banks	62.00	172.99
	Bank overdrafts and cash credit facility (secured)*	(1,147.39)	(1,269.40)
	Closing Balance of Cash & Cash Equivalents	**(1,340.61)**	**(1,077.78)**
	Cash on hand	7.23	7.60
	Balance With Banks	15.4	62.0
	Bank overdrafts and cash credit facility (secured)*	(1,363.2)	(1,147.4)
1	Figures in brackets represent cash out flows.		
2	The above Cash Flow statement has been prepared under the "Indirect Method" set out in Accounting Standard (Ind AS-7) on Statement of Cash flows issued by the Institute of Chartered Accountants of India.		
3	*Previous year`s comparative have been reclassified to confirm with current year's presentation wherever applicable.*		
*4	Bank overdrafts and cash credit facility are part of cash management system of the Company. Hence, considered as part of cash and cash equivalents		

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

SATHULURI & CO.
CHARTERED ACCOUNTANTS

Limited Review Report on Consolidated Unaudited Quarterly Financial Results of Astal Laboratories Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors
Astal Laboratories Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Astal Laboratories Limited** (the "Holding Company") and its subsidiary (the "Holding Company" and its subsidiary together referred to as "the Group"), for the quarter and half year ended 30th September, 2026, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Off: 11-13-1377/2, Flat No. 401, City Centre Complex, Margadarshi Colony, Kothapet, Hyderabad-500035.
Ph: 9391686797 Email: casathuluri93@gmail.com

4. The Statement includes the results of the following Subsidiary entities:

   (i) Sriven Pharmachem India Private Limited.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of One Wholly Owned Subsidiary included in the consolidated unaudited financial results, whose interim financial results reflect total revenue of Rs. **6,732.36** Lakhs, Rs. **12,885.13** Lakhs and Rs. **9,418.27** Lakhs, total net profit after tax of Rs. **597.92** Lakhs, Rs. **1169.40** Lakhs and Rs. **659.40** Lakhs and total comprehensive income of Rs. **597.92** Lakhs, Rs. **1169.40** Lakhs and Rs. **659.40** Lakhs, for the quarter and half year ended September 30, 2026 and for the period from 14th January to March 31, 2026 respectively as considered in the consolidated unaudited financial results, and

   Total Assets of Rs. **20,474.43** Lakhs and Rs. **19,313.92** Lakhs for the half year ended September 30, 2026 and from 14th January to March 31, 2026 respectively as considered in the consolidated unaudited financial statements, and

   Net cash outflows of Rs.**33.61** Lakhs, Rs. **488.06** Lakhs for the half year ended September 30, 2026 and the period from 14-01-2026 to 31-03-2026 respectively as considered in the consolidated unaudited Cash flow statement.



These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

For Sathuluri & Co.
Chartered Accountants
(FRN. No.006383S)

CA S S Prakash
Partner
M.No. 202710

UDIN : 26202710MYVXZW3895

Place: Hyderabad
Date : 13-11-2026

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER 2026

Rs. (In Lakhs)

Sr. No	Particulars	3 Months ended	Preceding 3 Months ended	Corsponding 3 Months Ended Ended in Previous Year	Year to Date Figures for Current Period Ended	Year to Date Figures for Previous Period Ended	Year to date figures for Previous year ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	**Revenue**						
	a) From operations	10,794.28	10,093.58	3,751.64	20,887.86	6,284.30	24,912.73
	b) Other Income (Refer to Note No.3)	25.83	13.81	3.27	39.63	8.88	22.15
	Total Revenue	**10,820.11**	**10,107.39**	**3,754.91**	**20,927.49**	**6,293.18**	**24,934.88**
2	**Expenses**						
	(a) Cost of Material Consumed	8,646.31	10,011.74	3,908.02	18,658.05	6,216.23	22,490.57
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(279.80)	(1,739.97)	(626.03)	(2,019.77)	(787.66)	(588.57)
		-	-	-	-	-	-
	(d) Employees Benefits expenses	276.48	314.82	41.83	591.30	86.55	502.15
	(e) Finance Cost	133.57	117.60	30.91	251.17	60.99	203.25
	(f) Depreciation amortization expenses	88.41	86.01	12.24	174.42	24.25	122.82
	(g) Other Expenses	421.99	282.18	40.94	704.17	66.53	431.62
	Total Expenses	**9,286.95**	9,072.38	**3,407.92**	**18,359.33**	**5,666.90**	**23,161.85**
3	**Profit from ordinary activities before exceptonal Items (1- 2)**	**1,533.15**	**1,035.01**	**346.99**	**2,568.16**	**626.28**	**1,773.03**
4	**Exceptional Items - Income/ (Expenses)**	-	-	-	-	-	-
5	**Profit from ordinary activities before tax (3 - 4)**	**1,533.15**	**1,035.01**	**346.99**	**2,568.16**	**626.28**	**1,773.03**
6	Tax Expenses						
	(a) Current Tax	500.91	119.70	90.41	620.61	136.02	268.04
	(b) Deferred Tax	55.20	(26.86)	(1.68)	28.34	23.03	34.05
7	**Profit/(Loss) for the period (5 -6)**	**977.04**	**942.17**	**258.26**	**1,919.21**	**467.22**	**1,470.94**
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-

ASTAL LABORATORIES LIMITED

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED
CIN: L74120UP1993PLC015605
Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
9	**Total Comprehensive Income, net of tax (7 + 8)**	**977.04**	**942.17**	**258.26**	**1,919.21**	**467.22**	**1,470.94**
10	**Paid up equity share capital** (Face Value of Rs.10/- each)	4,379.89	4,379.89	1,077.00	4,379.89	1,077.00	4,223.11
11	**Earning per share** (of Rs.10/-each) not annualised						
	(a) Basic	**2.231**	**2.188**	**2.395**	**4.419**	**4.338**	**8.620**
	(b) Diluted	**2.221**	**2.178**	**1.972**	**4.400**	**3.568**	**7.810**

NOTES:

1	The above Unaudited Consolidated Financial Results of the company for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and have been approved by the Board of Directors at its meeting held on 13th November, 2026.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website https://astallabs.com/
7	The Company has one Material Wholly Owned Subsidiary Company as on September 30, 2026. The requirement of Consolidation for the corresponding period ended and Year-to-Date Figures for Previous Period Ended as on 30.09.2025 was not applicable.

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina
Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026

(Rs. In Lakhs)

PARTICULARS		As at 30th Sep 2026 (Unaudited)	As at 31-March 2026 (Audited)
	ASSETS		
1	**Non - current assets**		
(a)	Property, plant and equipment	6,208.95	6,371.10
(b)	Right-of-use-asset	65.08	74.85
(c)	Intangible assets-Good will	20,320.17	20,320.17
(d)	Financial assets		
	(i) Loans	389.81	409.26
	(ii) Balance with Banks	379.56	343.59
(e)	*Other Non-current aasets*	39.05	39.67
	Total non-currrent assets	**27,402.62**	**27,558.64**
2	**Current assets**	-	-
(a)	Inventories	9,932.42	6,752.31
(b)	Financial assets	-	-
	(i) Trade receivables	15,969.35	15,689.58
	(ii) Cash and cash equivalents	25.15	70.26
(c)	Other Current assests	1,406.80	1,803.54
	Total current assets	**27,333.72**	**24,315.70**
	TOTAL ASSETS	**54,736.34**	**51,874.34**
	EQUITY AND LIABILITIES		
1	**Equity**		
(a)	Share capital	4,381.45	4,223.12
(b)	Other equity	31,358.40	29,152.53
	Total Equity	**35,739.84**	**33,375.65**
2	**Non-current liabilities**		
(a)	Financial liabilities		
	(i) Long-term borrowings	1,912.38	1,864.15
	(ii) Deferred tax liabilities (net)	114.58	86.24
	(iii) Lease Liabilities	56.71	64.78
(b)	Provisions	-	-
(c)	Other Non Current liabilities	-	-
	Total non-current liabilities	**2,083.67**	**2,015.17**
3	**Current liabilities**		
(a)	Financial liabilities		
	(i) Borrowings	3,328.53	3,044.18
	(ii) Lease Liabilities	16.21	16.21
	(iii) Trade payables	12,182.17	12,435.32
	(iv) Other financial liabilities	-	-
(b)	Provisions	-	-
(c)	Other current Liabilities	1,385.92	987.81

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

	Total current liabilities	16,912.83	16,483.52
	Total Liabilities	18,996.49	18,498.69
	TOTAL EQUITY AND LIABILITIES	54,736.34	51,874.34

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

STATEMENT OF STANDALONE UNAUDITED CASH FLOW AS ON SEPTEMBER 30, 2026

(Rs. In Lakhs)

	PARTICULARS	30th September, 2026 (Unaudited)	31st March, 2026 (Audited)
A)	**CASH FLOW FROM OPERATING ACTIVITIES**		
	Profit before tax for the year		
	Net Profit before exceptional and tax as Statement Profit & Loss (Increase in Reserves)	2,568.16	1,773.03
	Adjusted for :-	-	-
	Finance Cost	251.17	203.25
	Depreciation and amortisation	174.42	122.82
	Bad debts written off		
	Loss on sale/scrappin of Property, Plant and Equipments	(10.04)	-
	Finance Cost		
	Interest income	(29.59)	(22.15)
	Operating Profit before Working Capital Changes	**2954.12**	**2076.95**
	Adjusted for changes in working capital		
	Increase /(Decrease) in Trade Payables	(230.15)	4,534.52
	Increase /(Decrease) in Borrowings		
	Increase /(Decrease) in Other financial liabilities		
	Increase /(Decrease) in Other current liabilities	(222.49)	332.79
	Increase /(Decrease) in Other Non-current liabilities		
	Increase /(Decrease) in Provisions (except IT)		
	Increase /(Decrease) in Current Tax Liabilities (Net)		
	(Increase)/Decrease in Inventory	(3,180.11)	(588.56)
	(Increase)/Decrease in Trade receivables	(302.78)	(7,934.07)
	(Increase)/Decrease in Others current financial assets	0.63	(29.14)
	(Increase)/Decrease in Other current assets	396.75	1,353.23
	(Increase) / Decrease in Non-current Financial Assets		(1,413.52)
	Consolidation adjustment		
	Cash Generated From Operations	**(584.04)**	**(1,667.80)**
	Net Cash used in Operating Activities Before Extraordinary Items		
	Less: - Extraordinary Items		
	Cash Generated From Operations	**(584.04)**	**(1,667.80)**
	Less: - Taxes Paid	-	(102.08)
	Net Cash Flow/(used)From Operating Activities (A)	**(584.04)**	**(1,769.88)**
B)	**CASH FLOW FROM INVESTING ACTIVITIES**		
	(Increase) / Decrease in Other Non-Current assets	-	10.00
	Purchase of Fixed Assets	(77.35)	(139.26)
	Investment in Sriven Pharma-Cash Consideration	-	(29.63)
	(Issue) / Recovery of Loans and advances	19.45	-
	Deposits with Bank	(35.98)	(77.28)
	Interest income	29.59	19.16
	Proceeds From Sales/written off of Fixed Assets	84.88	-

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301
Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032
SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India
Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: https://astallabs.com/

	Net Cash Flow/(used) in Investing Activities (B)	**20.59**	**(217.01)**
C)	**CASH FLOW FROM FINANCING ACTIVITIES**		
	Procurement of Borrowings	253.25	-
	Interest Expense on Lease Liability	(3.85)	-
	Lease Lability	(8.07)	(22.34)
	Repayment of Borrowings	(171.99)	(143.34)
	Interest paid	(247.32)	(194.29)
	Shares/Warrents Amount Received	444.99	617.98
	Net Cash Flow/(used) From Financing Activities C)	***267.00***	***258.01***
	Net Increase/(Decrease) in Cash and Cash Equivalent (A+B+C)	**(296.44)**	**(1,728.88)**
	Opening balance of Cash and Cash Equivalent	**(2,825.28)**	**(1,096.40)**
	Cash on hand	7.64	0.02
	Balance With Banks	62.63	172.99
	Bank overdrafts and cash credit facility (secured)*	(2,895.55)	(1,269.40)
	Closing balance of Cash and Cash Equivalent	**(3,121.72)**	**(2,825.28)**
	Cash on hand	9.34	7.64
	Balance With Banks	15.81	62.63
	Bank overdrafts and cash credit facility (secured)*	(3,146.87)	(2,895.55)

The above Cash Flow Statement has been prepared under the Indirect Method ' as set out lnd AS - 7 "Statement of Cash Flows".

//By the order of the Board//
For Astal Laboratories Limited

Place: Hyderabad
Date: 13/11/2026

SUDHEER KARNA KANKANALA
(Wholetime Director)
DIN: 07591466